-
Kanghong’s Escitalopram Oral Solution Receives NMPA Marketing Approval
•
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its Category 3 chemical product escitalopram oral solution. The product is approved to treat depression and panic disorder with or without agoraphobia, marking a significant milestone in the…
-
Tonghua Dongbao Receives NMPA Approval for THDBH151 Clinical Study in Gout and Hyperuricemia
•
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its dual-targeted drug candidate THDBH151 in gout and hyperuricemia. This marks a significant step forward in the development of innovative treatments for these conditions. Existing Therapies and…
-
Innovent Biologics Announces Strategic Partnerships to Form Tumor Diagnosis and Treatment Alliance
•
China-based Innovent Biologics (HKG: 1801) has announced a series of strategic partnerships with compatriot firms Xinyi Biology, LBP Medicine, Xiangxin Biotechnology, Wuhan HealthCare Biotechnology Co., Ltd, Amoy Diagnostics Co., Ltd, and Shanghai OrigiMed Co., Ltd. The aim is to jointly establish a tumor diagnosis and treatment biosphere alliance. Financial details…
-
BioNTech Ships First COVID-19 Vaccine Batches to China
•
BioNTech is reportedly in the process of shipping the first batches of its COVID-19 vaccines to China, following a state-level agreement between China and Germany that allows German expats access to the product. The news was confirmed by a German government spokesperson, as reported by Reuters. Agreement and Vaccine AccessChancellor…
-
Merck Launches Noxafil in China for Antifungal Treatment
•
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced the official market launch of its Noxafil (posaconazole) in China. Noxafil is an antifungal agent used to prevent invasive aspergillosis and candida infection and treat invasive aspergillosis. Drug Profile and Dosage FormsNoxafil is a next-generation triazole antifungal drug with…
-
Hinova’s PROTAC Drug HP518 Accepted for FDA Review in mCRPC
•
China-based biopharma Hinova Pharmaceuticals has announced that a clinical trial filing for its androgen receptor (AR) targeted proteolysis-targeting chimeric (PROTAC) drug HP518 in metastatic castration-resistant prostate cancer (mCRPC) has been accepted for review by the US FDA. The study in question is an open-label study assessing the safety, pharmacokinetics, and…
-
Fosun Kite’s CAR-T Therapy FKC889 Approved for Clinical Trials in China
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its subsidiary Fosun Kite Biotechnology Co., Ltd’s chimeric antigen receptor (CAR)-T cell therapy FKC889 has obtained clinical trial approval in mainland China to treat adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).…
-
Shanghai Outlines Plans to Boost Healthcare and Pharma Industry
•
Liu Wei, director of the market orders and trade division of the Shanghai Commerce Commission, recently outlined plans to boost the local healthcare and pharmaceutical industry ecosystem at the China Pharmaceutical Industry Information Annual Conference. His speech follows the release in November of “Policies and Measures to Support the Acceleration…
-
Yantai Dongcheng Receives NMPA Approval for F18 PET Imaging Study
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for an F18 product for use in positron emission tomography (PET) imaging of fibroblast activating protein (FAP)-positive lesions. This marks a significant step forward in…
-
Biomica Raises Funds for Tumor Immunity and IBD Drug Development
•
Israel-based start-up Biomica has reportedly raised an undisclosed amount of money via another financing round, led by Shanghai HealthCare Capital and its parent company Evogene. The proceeds will be used for a Phase I clinical study for its tumor immunity project BMC128, GMPc-compliant manufacturing for BMC333 for inflammatory bowel disease…
-
Redpine Medical Raises ‘Hundreds of Millions’ in Series C Financing Round
•
Redpine Medical, a single-use endoscope maker based in Guangzhou, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by Yuexiu Industrial Investment Fund. Other investors included Eight Roads, Guoju Venture Capital, Caixin Private Placement, and others. The proceeds will be used for manufacturing capacity…
-
Yipinhong’s AR882 Receives NMPA Approval for Gout Clinical Trial
•
China-based Yipinhong Pharmacy Co., Ltd (SHA: 300723) has announced that its pipeline candidate AR882, under co-development with Arthrosi Therapeutics Inc., has obtained clinical trial approval from the National Medical Products Administration (NMPA). The targeted indication is gout, a condition characterized by high levels of uric acid in the blood. Drug…
-
Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor
•
China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1, US11530195B1) in relation to a development project titled “Coronavirus 3CL Protease Inhibitor Development,” in collaboration with Shaanxi University of Science and Technology. The patents cover “PROTACs [proteolysis-targeting chimeric molecules] based on VHL ligand targeting coronavirus…
-
Sibionics Raises RMB 500 Million in Series D Financing Round
•
Shenzhen-based chronic disease device maker Sibionics has reportedly raised close to RMB 500 million (USD 71.7 million) in a Series D financing round. The round was led by Shanghai Healthcare Capital and Guangdong Traditional Chinese Medicine Healthcare Fund, with contributions from Industrial Securities Capital, Next Capital, and China New Town…
-
Waker Bioscience Raises Angel Funding for ISA Technology Upgrades
•
Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens of millions” of renminbi in an angel financing round, solely led by BGI Co-Win. The proceeds will be used for technology upgrades, team building, testing business development, and laboratory platform automation construction. Company Background and…
-
InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination
•
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center for Drug Evaluation (CDE) to start a Phase II clinical trial assessing a combination of orelabrutinib with tafasitamab and lenalidomide in patients with relapsed/refractory (r/r) non-Hodgkin’s lymphoma (nHL). This approval marks a significant step in…
-
Ronovo Surgical Raises Pre-Series B Funding for Surgical Robot Development
•
Ronovo Surgical, a minimally invasive surgery device maker based in Shanghai, has reportedly raised “tens of millions” of US dollars in a Pre-Series B financing round led by LongRiver Investments. Other investors included Lilly Asia Ventures, Vivo Capital, Matrix Partners, and GGV Capital. The proceeds will be used for multi-specialty…
-
PingAn Good Doctor Partners to Establish Lifestyle Medicine
•
China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, has struck a partnership with the Shenzhen Hospital of Southern Medical University and Shenzhen Community Health Association (SCHA) to establish lifestyle medicine. Financial details of the partnership were not disclosed. PingAn Good Doctor’s ServicesPingAn Good…
-
JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development
•
China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a strategic collaboration with its major shareholder Juno. The deal sees Juno grant licenses to patents and know-how in order to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T cell therapy targeting the solid…
-
Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm
•
China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the Russian pharmaceutical company Binnopharm Group, focused on 9MW0113, 9MW0321, and 9MW0311, Mabwell’s biosimilar versions of adalimumab and denosumab. Binnopharm will have exclusive rights to develop, register, manufacture, and market the drugs with a status of…
